XC8 in the Treatment of Patients With the Eosinophilic Phenotype of Bronchial Asthma
Status:
Completed
Trial end date:
2021-08-27
Target enrollment:
Participant gender:
Summary
A multicenter, double-blind, randomized, pilot study in parallel groups to assess the
efficacy and safety of XC8 at a dose of 100 mg versus placebo over a 12-week treatment period
in non-smoking patients with a confirmed bronchial asthma (BA) and the eosinophil blood level
2 times within 1 week interval of ≥ 300 cells/μl.
Study design was developed by Chemlmmune Therapeutics LLC, Russia in cooperation with Eurrus
Biotech GmbH, Austria.